Business
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs FT819, FT839, and FT836, will be featured at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held in Boston
About this update from Fate Therapeutics, Inc.
[{"type":"image","alt":"Fate Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Fate Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":153,"url":"https://media.zenfs.com/en/globenewswire.com/2373fd33b6ce4e09e3903a1c614dd79c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SmStO_D_4FY01KgSmG1zig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNA--/https://media.zenfs.com/en/globenewswire.com/2373fd33b6ce4e09e3903a1c614dd79c","width":300,"height":153}},"lazy":false},{"type":"text","content":"SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs FT819, FT839, and FT836, will be featured at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held in Boston, MA, May 11–15, 2026.","length":522,"tagName":"p"},{"type":"text","content":"Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to background maintenance therapy without the use of conditioning chemotherapy to drive B cell depletion and improve patient outcome.","length":325,"tagName":"p"},{"type":"text","content":"The Company will also deliver an oral presentation on FT839, its next-generation, off-the-shelf dual-CAR T cell therapy designed to simultaneously target CD19 and CD38 to eliminate pathogenic B cells, plasma cells, and activated T and NK cells, while selectively sparing non-activated immune cells. This multi-antigen targeting approach is designed to offer a unique treatment option for patients with difficult-to-treat autoimmune diseases that are multicellular in pathology, including rheumatoid arthritis and type 1 diabetes.","length":529,"tagName":"p"},{"type":"text","content":"Additionally, the Company will present preclinical data on FT836, its next-generation, off-the-shelf CAR T-cell therapy targeting the pan-tumor stress ligands MICA/B. FT836 is shown to demonstrate potent anti-tumor activity in preclinical studies across a broad range of liquid and solid tumors w...